



## BioCryst to Present at Upcoming Investor Conference

August 21, 2025

RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (Nasdaq: BCRX) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September 4, 2025, at 9:45 a.m. ET.

The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst's website at [www.biocryst.com](http://www.biocryst.com).

### About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO<sup>®</sup> (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit [www.biocryst.com](http://www.biocryst.com) or follow us on [LinkedIn](#).

BCRXW

### **Contact:**

#### **Investors:**

[investorrelations@biocryst.com](mailto:investorrelations@biocryst.com)

#### **Media:**

[media@biocryst.com](mailto:media@biocryst.com)